secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2023-01-24T23:59:59+00:00
Accession:  0001104659-23-006194
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen reports positive Phase 1 PRGN-2012 data: 50% complete response in RRP patients
--------------------------------------------------------------------------------

- 50% of RRP patients at Dose Level 2 achieved Complete Response, requiring no post-treatment surgeries.
- Median annual RRP surgeries dropped from 6.5 pre-treatment to 0.5 post-treatment at Dose Level 2.
- PRGN-2012 well-tolerated with no dose-limiting toxicities and no treatment-related Grade ≥3 adverse events.
- Preliminary cash, equivalents, and investments totaled ~$56M as of Dec 31, 2022; restricted cash ~$43.7M.
- Phase 2 study enrolling; 32 patients enrolled at Dose Level 2 to date; FDA discussions advancing for regulatory strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000110465923006194/0001104659-23-006194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000110465923006194/tm234280d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-006194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer